Changeflow GovPing Pharma & Drug Safety Methods for Assaying Enriched Nucleic Acids Usi...
Routine Notice Added Final

Methods for Assaying Enriched Nucleic Acids Using Complementary Probes

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO published patent application US20260098304A1 covering methods for assaying enriched nucleic acids using probes with sequences complementary to RNA expression products to determine expression levels of multiple genes. The application was filed on October 3, 2024 by inventors including Charles M. Perou, Joel S. Parker, and others. The claimed methods enable enrichment of nucleic acid molecules for gene expression analysis in biological samples.

What changed

The USPTO published a patent application for methods of detecting RNA expression using complementary probes to assay enriched nucleic acids derived from biological samples. The application claims methods for determining expression levels of multiple genes through probe-based enrichment of RNA-derived nucleic acid molecules.

Competitors developing RNA-based diagnostics or gene expression analysis technologies should review the application claims for potential infringement risks and assess freedom to operate. This publication establishes a priority date of October 3, 2024 for the claimed inventions.

What to do next

  1. Monitor for patent grant
  2. Conduct freedom-to-operate analysis

Archived snapshot

Apr 13, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

METHODS FOR ASSAYING ENRICHED NUCLEIC ACIDS

Application US20260098304A1 Kind: A1 Apr 09, 2026

Inventors

Charles M. Perou, Joel S. Parker, James Stephen Marron, Andrew Nobel, Philip S. Bernard, Matthew J. Ellis, Elaine Mardis, Torsten O. Nielsen, Maggie Chon U. Cheang

Abstract

In an aspect, a method comprises providing a biological sample of a subject, and assaying nucleic acid molecules derived from RNA expression products of the biological sample to determine an RNA expression level of a plurality of genes, wherein the assaying comprises use of probes having sequences complementary to the nucleic acid molecules derived from the RNA expression products, to enrich the nucleic acid molecules for the plurality of genes.

CPC Classifications

C12Q 1/6886 C12N 15/1096 C12Q 1/6813 C12Q 1/6869 C12Q 2600/158

Filing Date

2024-10-03

Application No.

18905647

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260098304A1

Who this affects

Applies to
Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent application Biomedical research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!